Xintelas jänkarpartner

Jänkarna har onekligen en snygg och informativ hemsida. In och kolla. 

 EQGen Biomedical is based in the US and is the exclusive licensee of a proprietary, next-generation stem cell treatment for equine osteoarthritis and joint disease (EQSTEM® - Xintela AB, Sweden).

The globally patented technology leverages a unique, proprietary method to purify multipotent cell populations using stem cell marker integrin α10β1. Integrin α10β1-selected MSCs cell populations show a superior ability to adhere to damaged cartilage and exposed subchondral bone in explants and reduction in lameness and joint pathology.

EQGen and Xintela are collaborating on clinical development and commercialization of the technology for the treatment of joint disease in equine, canine and camelid patients.

Previous studies of EQSTEM® have shown extremely promising results. In-vitro analyses have demonstrated greater ability to adhere to damaged cartilage and enhanced chondrogenic differentiation ability. Multiple in-vivo studies have been performed, including a 25-patient analysis with post traumatic OA showing reduced cartilage damage and bone sclerosis, reduced pain, and detection of cells at the cartilaginous surface 52 days post injection.